NYAS Conferences
New York Academy of Sciences
left end
Search
divider divider feedback right end
Annals of the New York Academy of Sciences Annals of the New York Academy of Sciences login

Main

Browse Volumes

Forthcoming Volumes

Annals PrePrints

Annals Extra

E-mail Alerts

Subscriptions & Orders

New Proposals

Author Guidelines

About Annals

Help

Get free Annals volume as a NYAS member: http://www.nyas.org/annalsreaderhw
Issue 1044 coverHEMATOPOIETIC STEM CELLS V Volume 1044 published June 2005
Ann. N.Y. Acad. Sci. 1044: 94–108 (2005). doi: 10.1196/annals.1349.013
Copyright © 2005 by the New York Academy of Sciences
description | purchase volume purchase this volume

This Volume
Table of Contents
Description
This Article
Full Text
Full Text (PDF)
Services
Similar articles in this journal
Similar articles in PubMed
Alert me to new issues of the journal
Download to citation manager
Citing Articles
Citing Articles via Google Scholar
Google Scholar
Articles by STEIDL, U.
Articles by KRONENWETT, R.
Search for Related Content
PubMed
PubMed Citation
Articles by STEIDL, U.
Articles by KRONENWETT, R.
Distinct Gene Expression Pattern of Malignant Hematopoietic Stem and Progenitor Cells in Polycythemia Vera

ULRICH STEIDLa,b, THOMAS SCHROEDERa, CHRISTIAN STEIDLc, GUIDO KOBBEa, THORSTEN GRAEFa, SIMONE BORKa, SABRINA PECHTELa, SLAWOMIR KLISZEWSKIa, ANDREA KUENDGENa, ULRICH P. ROHRa, ROLAND FENKa, MICHAEL SCHROEDERd, DETLEF HAASEc, RAINER HAASa AND RALF KRONENWETTa

aDepartment of Hematology, Oncology, and Clinical Immunology, Heinrich Heine University, Duesseldorf, Germany
bHarvard Institutes of Medicine, Boston, Massachusetts, USA
cDepartment of Hematology and Oncology, Georg August University, Goettingen, Germany
dDepartment of Hematology and Oncology, and Clinical Immunology, St. Johannes Hospital, Duisburg, Germany

Address for correspondence: Priv.-Doz. Dr. med. Ralf Kronenwett, Klinik für Hämatologie, Onkologie und klinische Immunologie, Heinrich-Heine-Universität Düsseldorf, Moorenstr. 5, D-40225 Düsseldorf, Germany. Voice: +49-211-81-17720; fax: +49-211-81-18853. kronenwett{at}med.uni-duesseldorf.de

Polycythemia vera (PV) is a chronic myeloproliferative disorder with an expansion of multipotent hematopoietic progenitor cells. Although it is known that hematopoietic progenitors in PV are erythropoietin independent and hypersensitive to several cytokines, the molecular oncogenic mechanisms in PV are largely unknown. In this study, we examined gene expression profiles of CD34+ cells from bone marrow of patients with de novo PV and from healthy volunteers to identify molecular changes associated with the malignant growth of hematopoietic stem and progenitor cells in this myeloproliferative disorder. Using cDNA arrays, we found significant differences (P < .01) in the expression of 107 genes. Proapoptotic genes (CASP2, CASP3, DAPK1, ALG2) were expressed at lower levels in PV-CD34+ cells, reflecting a lower apoptotic activity. Fibrosis-stimulating growth factors (transforming growth factor ß1, transforming growth factor ß2, bone morphogenetic protein 2, and endothelial growth factor) were expressed at significantly higher levels in PV-CD34+ cells. Furthermore, PV-CD34+ cells overexpressed several receptors, protein kinases, and proteasome subunits, which might be targets for directed therapeutic approaches. It is interesting that three retinoid receptors were overexpressed in PV-CD34+ cells—retinoic acid receptor ß (RARß), retinoid X receptor ß (RXRß), and cellular retinoic acid binding protein 2 (CRABP2). Using methylcellulose colony-forming assays, we found that the formation of erythroid colonies derived from PV hematopoietic progenitors was inhibited by all-trans-retinoic acid (ATRA), a natural ligand of those receptors, in a dose-dependent manner, showing a maximum inhibition of 89% at 10 µM; the growth of myelomonocytic colonies was not significantly affected. These data suggest that the use of ATRA could be of therapeutic benefit for patients with PV.

Key Words: polycythemia vera • CD34+ cells • gene expression • detoxification enzymes • retinoid receptors • opioid µ1 receptor • proteasome






footerLeft footerRight